TP53 and neoplasm: It is demonstrated that MDM4 (or MDMX) is highly expressed in ductal epithelial breast cells and its down-regulation is sufficient to significantly mitigate tumor growth and progression, a fact that suggest the targeting of MDMX as an attractive strategy for the treatment of BrCas that express wt p53 (~70% of all cases) [90].